Fate Therapeutics Inc. Submits SEC Filing

Strategic Insights -

A U.S. Securities and Exchange Commission (SEC) filing by Fate Therapeutics Inc. was posted on February 7, 2023. The company, operating in the biopharmaceutical industry, submitted a single document with form 4, which reports on transactions involving directors, officers, and major shareholders. This filing is a requirement for companies with securities registered under Section 12 of the Securities Exchange Act of 1934. The document provides information on the reporting person's relationship to the company and transactions involving equity securities.

Key Takeaways:

  • Fate Therapeutics Inc. submitted a SEC filing on February 7, 2023, under the form number 0001209191-23-007497.
  • The SEC filing reports on transactions involving directors, officers, and major shareholders of Fate Therapeutics Inc.
  • The company's SIC code is 2836, which categorizes it as a biological products manufacturer.
  • The filing provides information on the reporting person's relationship to the company and transactions involving equity securities.
  • According to SEC regulations, directors, officers, and major shareholders must file Form 3 for the initial statement of ownership and Form 4 for changes in ownership.
  • The company's San Diego location is 12278 SCRIPPS SUMMIT DRIVE, CA 92131, and can be contacted at 858.875.1803.

Statistics:

  • Date of the SEC filing: February 7, 2023.
  • Form number: 0001209191-23-007497.
  • Number of documents submitted: 1.
  • SIC code: 2836.
  • Company address: 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131.
  • Company phone number: 858.875.1803.

Sources:

  • SEC filing on Fate Therapeutics Inc. Accession Number: 0001209191-23-007497 and Document ID: 0001193125-23-006934
  • U.S. Securities and Exchange Commission (SEC) website: https://www.sec.gov/Archives/edgar/data/1434316/0001209191-23-007497-index.html